When Direct Health-Care Professional Communications Have an Impact on Inappropriate and Unsafe Use of Medicines

被引：28

作者：

Reber, K. C. ^{[1
]}

Piening, S. ^{[2
]}

Wieringa, J. E. ^{[1
]}

Straus, S. M. J. M. ^{[3
,4
]}

Raine, J. M. ^{[5
]}

de Graeff', P. A. ^{[2
,3
]}

Haaijer-Ruskamp, F. M. ^{[2
]}

Mol, P. G. M. ^{[2
,3
]}

机构：

[1] Univ Groningen, Dept Mkt, Groningen, Netherlands

[2] Univ Groningen, Univ Med Ctr Groningen, Dept Clin Pharmacol, Groningen, Netherlands

[3] Dutch Med Evaluat Board, Utrecht, Netherlands

[4] Erasmus MC, Dept Med Informat, Rotterdam, Netherlands

[5] Med & Healthcare Prod Regulatory Agcy, London, England

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2013年 / 93卷 / 04期

关键词：

ADVERSE DRUG-REACTIONS; REGULATORY ACTION; EUROPEAN-UNION; SAFETY; WARNINGS; NETHERLANDS; SPECIALISTS;

D O I：

10.1038/clpt.2012.262

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Serious safety issues relating to drugs are communicated to health-care professionals via Direct Health-Care Professional Communications (DHPCs). We explored which characteristics determined the impact of DHPCs issued in the Netherlands for ambulatory-care drugs (2001-2008). With multiple linear regression, we examined the impact on the relative change in new drug use post-DHPC of the following: time to DHPC, trend in use, degree of innovation, specialist drug, first/repeated DHPC, DHPC template, and type of safety issue. DHPCs have less impact on use of specialist drugs than nonspecialist drugs (P < 0.05).The DHPCs' impact increased after availability of a template emphasizing the main problem (P < 0.05), and for safety issues with a risk of death and/or disability (both P < 0.05) (adjusted R-2 = 0.392). Risk communication can be effective, specifically in case of well-structured information, and very serious safety issues. Effectiveness may improve by tailoring DHPCs and adding other communication channels, for example for drugs that are increasingly being used.

引用

页码：360 / 365

页数：6

共 25 条

[1]

[Anonymous], 2018, Econometric Analysis, DOI DOI 10.1093/GERONB/GBQ006

[2] Impact of FDA Drug Risk Communications on Health Care Utilization and Health Behaviors A Systematic Review [J].